Alchemab Therapeutics
Founded 2019 · 73 employees on LinkedIn · 9 known investors
Find your way into Alchemab Therapeutics
83 people in our graph share verified history with the Alchemab Therapeutics team — schools, employers, funds. One of them is your warm intro.
Alex Badamchi-Zadehunlockedknows Jane Osbourn · together at Alchemab Therapeutics
×9knows the team · via Dementia Discovery Fund
×2knows the team · via Alchemab Therapeutics
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.
Founders & leadership
JO
Investors · 9
SV Health Investors✓ verifiedBoston · $1M – $20M
DCVC Bio✓ verifiedPalo Alto
RA Capital✓ verifiedBoston
Dementia Discovery FundLondon
Lightstone VenturesPortola Valley
Ono Venture Investment, Inc.South San Francisco
British Business Bankreported · 2 sourcesSheffield
British Patient CapitalreportedLondon
DCVC (Data Collective)reportedPalo Alto · $5M – $25M
In the news
Frequently asked questions
- What does Alchemab Therapeutics do?
- Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.
- Who are Alchemab Therapeutics's investors?
- Alchemab Therapeutics's investors include SV Health Investors, DCVC Bio, RA Capital, Dementia Discovery Fund, Lightstone Ventures, Ono Venture Investment, Inc., British Business Bank, British Patient Capital and 1 more.